Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 10.7% Higher – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price rose 10.7% on Wednesday . The stock traded as high as $12.05 and last traded at $11.78. Approximately 29,323,578 shares traded hands during trading, an increase of 21% from the average daily volume of 24,262,922 shares. The stock had previously closed at $10.64.

Wall Street Analysts Forecast Growth

RXRX has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp cut their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Stock Performance

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $4.29 billion, a price-to-earnings ratio of -7.18 and a beta of 0.86. The firm’s fifty day moving average price is $7.38 and its 200 day moving average price is $6.95.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals during the third quarter worth $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $26,000. Private Trust Co. NA acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $27,000. GAMMA Investing LLC lifted its position in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after buying an additional 4,091 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.